Lisinopril reverses left ventricular hypertrophy through improved aortic compliance

Hypertension

Volumn 28, Issue 3, 1996, Pages 457-463

  Shimamoto, Hiroyuki ^a,b   Shimamoto, Yoriko ^a  

^a PIA Nakamura Hospital   (Japan)

^b NONE   (Japan)

Author keywords

compliance; hypertrophy, left ventricular; lisinopril; nifedipine

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; NIFEDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SUSTAINED RELEASE PREPARATION;

EID: 0029795660     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.3.457     Document Type: Article

References (41)

1. Liebson PR, Savage DD. Echocardiography in hypertension: a review. I. Left ventricular wall mass, standardization, and ventricular function. Echocardiography. 1986;3:181-218.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322:1561-1566.
3. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Frohlich ED. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. Am J Cardiol. 1988;62:912-916.
4. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Prevention of the development of heart failure and the regression of cardiac hypertrophy by captopril in the spontaneously hypertensive rats. Eur Heart J. 1983;4:143-148.
5. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
6. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors: the Framingham Heart Study. Ann Intern Med. 1988;108:7-13.
7. Frohlich ED. Overview of hemodynamic and nonhemodynamic factors associated with left ventricular hypertrophy. J Mol Cell Cardiol. 1989;21(suppl V):3-10.
8. Castellano M, Muiesan ML, Rizzoni D, Beschi M, Pasini G, Cinelli A, Salvetti M, Porteri E, Bettoni G, Kreutz R, Lindpaintner K, Rosei EA. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population: the Vobarno study. Circulation. 1995;91:2721-2724.
9. Dzau VJ, Safar ME. Large conduit arteries in hypertension: role of the vascular renin-angiotensin system. Circulation. 1988;77:947-954.
10. Shimamoto H, Shimamoto Y. Lisinopril improves aortic compliance and renal flow: comparison with nifedipine. Hypertension. 1995; 25:327-334.
11. Takahashi M, Sasayama S, Kawai C, Kotoura H. Contractile performance of the hypertrophied ventricle in patients with systemic hypertension. Circulation. 1980;62:116-126.
12. Devereux RB. Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
13. Shimamoto H, Shimamoto Y, Kito H, Kawazoe K, Fujita T, Okamoto M. Doppler echocardiographic measurement of cardiac output in man using mitral annulus method. J Clin Ultrasound. 1992;20:263-270.
14. Tsuji U, Nakanishi T, Nakai K, Shiomi J, Funahashi S. Liquid-chromatographic measurement of catecholamines in plasma and urine using HLC-8030. Kiki Shiyaku. 1988;11:635-641.
15. Morimoto T, Aoyama M, Gotoh E, Shionoiri H. A method of radioimmunoassay of plasma angiotensin II using Florisil. Folia Endocrinol Jpn. 1983;59:215-229.
16. Swynghedauw B, Moalic JM, Delcayre C. The origins of cardiac hypertrophy. In: Swynghedauw B, ed. Research in Cardiac Hypertrophy and Failure. Paris, France: INSERM; 1990:23-50.
17. Kent RL, Mann DL, Cooper G IV. Signals for cardiac muscle hypertrophy in hypertension. J Cardiovasc Pharmacol. 1991;17(suppl 2):S7-S13.
18. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1969;56:370-382.
19. Schölkens BA, Linz W, Martorana PA. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: beyond blood pressure reduction. J Cardiovasc Pharmacol. 1991;18(suppl 2): S26-S30.
20. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990;259:H610-H618.
21. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural and endocrine dependence. Circulation. 1991;83:13-25.
22. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
23. Nagano M, Higaki J, Mikami H, Nakamura M, Higashimori K, Katahira K, Tabuchi Y, Moriguchi A, Nakamura F, Ogihara T. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens. 1991;9:595-599.
24. Safar ME, Toto-Moukouo JJ, Bouthier JA, Asmar RE, Levenson JA, Simon AC, London GM. Arterial dynamics, cardiac hypertrophy, and antihypertensive trealment. Circulation. 1987;75(suppl 1):I-156-I-161.
25. Simon AC, Safar ME, Levenson JA, London GM, Levy BI. Chau NP. An evaluation of large arteries compliance in man. Am J Physiol. 1979;237:H550-H554.
26. Kifer I, Dzau VJ. Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ Res. 1987;60:422-428.
27. Assad MM, Antonaccio MJ. Vascular wall renin in spontaneously hypertensive rats: potential relevance to hypertension maintenance and antihypertensive effect of captopril. Hypertension. 1982;4: 487-493.
28. Okamura T, Miyazaki M, Inagami T, Toda N. Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats. Hypertension. 1986;8:560-565.
29. Simon AC, Levenson JA, Bouthier JD, Safar ME. Captopril induced changes of large arteries in essential hypertension: regional hemodynamics following captopril therapy. Am J Med. 1984;76:71-76.
30. Richer C, Thuillez C, Giudicelli JF. Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer. J Cardiovasc Pharmacol. 1987:9:94-102.
31. Geisterfer AAT, Owens GK. Hypertrophic response of cultured vascular smooth muscle cells to angiotensin II. Fed Proc. 1986;45:584.
32. Loudon M, Bing RF, Thurston H, Swales JD. Arterial wall uptake of renal renin and blood pressure control. Hypertension. 1983;5: 629-634.
33. Safar ME, Laurent SL, Bouthier JD. London GM, Mimran AR. Effect of converting enzyme inhibitors on hypertensive large arteries in humans. J Hypertens. 1986;4(suppl 5):S285-S289.
34. Rorive GL, Carlier PG, Foidart JM. The structural responses of the vascular wall in experimental hypertension. In: Zanchetti A. Tarazi RC, eds. Handbook of Hypertension. Volume 7: Pathophysiology of Hypertension. Cardiovascular Aspects. Amsterdam, Netherlands: Elsevier Scientific Publishers BV; 1986:427-453.
35. Gardin JM, Drayer JIM, Weber M, Rohan MK, Knoll M, Shu VWC, Garcia R, Brewer D, Henry WL. Doppler echocardiographic assessment of left ventricular systolic and diastolic function in mild hypertension. Hypertension. 1987;9(suppl II):II-90-II-96.
36. Pearson AC, Labovitz AJ, Mrosek D, Williams GA. Assessment of diastolic function in normal and hypertrophied hearts: comparison of Doppler echocardiography and M-mode echocardiography. Am Heart J. 1987;113:1417-1425.
37. Capasso JM, Strobeck JE, Sonnenblick EH. Myocardial mechanical alterations during gradual onset of long term hypertension in rats. Am J Physiol. 1981;241:H435-H441.
38. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
39. O'Rourke M. Systolic blood pressure: arterial compliance and early wave reflection, and their modification by antihypertensive therapy. J Hum Hypertens. 1989;3:47-52.
40. Asmar RG, Journo HJ, Lacolley PJ, Santoni JP, Billaud E, Levy BI, Safar ME. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens. 1988;6(suppl 3):S33-S39.
41. Bielen EC, Fagard RH, Lijnen PJ, Tjandra-Maga TB, Verbesselt R, Amery AK. Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. Am J Cardiol. 1992;69:1200-1206.